Pharmacokinetic and pharmacodynamic interactions between the hepatitis C virus protease inhibitor, boceprevir, and the oral contraceptive ethinyl estradiol/norethindrone.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Lin WH;Lin WH; Feng HP; Shadle CR; O'Reilly T; Wagner JA; Butterton JR
  • Source:
    European journal of clinical pharmacology [Eur J Clin Pharmacol] 2014 Sep; Vol. 70 (9), pp. 1107-13. Date of Electronic Publication: 2014 Jul 05.
  • Publication Type:
    Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Springer Country of Publication: Germany NLM ID: 1256165 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-1041 (Electronic) Linking ISSN: 00316970 NLM ISO Abbreviation: Eur J Clin Pharmacol Subsets: MEDLINE
    • Publication Information:
      Original Publication: Berlin, New York, Springer.
    • Subject Terms:
      Contraceptives, Oral, Combined/*pharmacokinetics ; Contraceptives, Oral, Combined/*pharmacology ; Ethinyl Estradiol/*pharmacokinetics ; Ethinyl Estradiol/*pharmacology ; Norethindrone/*pharmacokinetics ; Norethindrone/*pharmacology ; Proline/*analogs & derivatives ; Protease Inhibitors/*pharmacology; Adolescent ; Adult ; Contraceptives, Oral, Combined/adverse effects ; Contraceptives, Oral, Combined/blood ; Drug Combinations ; Drug Interactions ; Ethinyl Estradiol/adverse effects ; Ethinyl Estradiol/blood ; Female ; Follicle Stimulating Hormone/blood ; Hepacivirus ; Humans ; Luteinizing Hormone/blood ; Norethindrone/adverse effects ; Norethindrone/blood ; Progesterone/blood ; Proline/adverse effects ; Proline/pharmacology ; Protease Inhibitors/adverse effects ; Sex Hormone-Binding Globulin/analysis ; Young Adult
    • Abstract:
      Purpose: The purpose of this study was to examine drug interactions between boceprevir, a hepatitis C virus NS3/4A protease inhibitor, and a combined oral contraceptive containing ethinyl estradiol (EE) and norethindrone (NE).
      Methods: A single-center, open-label study was conducted in 20 healthy female volunteers. In three consecutive 28-day treatment periods, subjects received EE/NE (0.035 mg/1 mg; 21 days on, 7 days off). During period 3, subjects also received boceprevir (800 mg three times daily) for 28 days.
      Results: Coadministration of boceprevir with EE/NE did not affect NE AUC0-24 but slightly reduced NE C max. Geometric mean ratios (GMRs) for NE AUC0-24 and C max with EE/NE alone and EE/NE plus boceprevir were 0.96 (90% confidence interval (CI), 0.87-1.06) and 0.83 (90% CI, 0.76-0.90). Coadministration of boceprevir with EE/NE reduced EE AUC0-24 and C max by 26 and 21%, with GMRs of 0.74 (90% CI, 0.68-0.80) and 0.79 (90% CI, 0.75-0.84). Boceprevir had no effect on mid-cycle luteinizing hormone (LH), follicle-stimulating hormone (FSH), or sex hormone-binding globulin levels, and progesterone concentrations remained <1 ng/ml during the luteal phase. Adverse events reported in this study were consistent with the well-established safety profile of boceprevir.
      Conclusion: Serum progesterone, LH, and FSH levels indicate that ovulation was suppressed during coadministration of boceprevir with EE/NE. Coadministration of boceprevir with combined oral contraceptives containing EE and ≥1 mg of NE is therefore unlikely to alter contraceptive effectiveness. The ovulation suppression activity of oral contraceptives containing lower doses of NE, and of other forms of hormonal contraception during coadministration with boceprevir, has not been established.
    • References:
      Drug Metab Dispos. 2004 Nov;32(11):1209-12. (PMID: 15304426)
      Antimicrob Agents Chemother. 2006 Mar;50(3):1013-20. (PMID: 16495264)
      Drug Metab Dispos. 2011 Mar;39(3):510-21. (PMID: 21123164)
      N Engl J Med. 2011 Mar 31;364(13):1195-206. (PMID: 21449783)
      Clin Pharmacokinet. 2004;43(10):673-84. (PMID: 15244497)
      J Clin Pharmacol. 2012 Oct;52(10):1574-83. (PMID: 22039291)
      N Engl J Med. 2011 Mar 31;364(13):1207-17. (PMID: 21449784)
    • Accession Number:
      0 (Contraceptives, Oral, Combined)
      0 (Drug Combinations)
      0 (Protease Inhibitors)
      0 (Sex Hormone-Binding Globulin)
      37270-71-6 (norethindrone acetate, ethinyl estradiol, ferrous fumarate drug combination)
      423D2T571U (Ethinyl Estradiol)
      4G7DS2Q64Y (Progesterone)
      89BT58KELH (N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide)
      9002-67-9 (Luteinizing Hormone)
      9002-68-0 (Follicle Stimulating Hormone)
      9DLQ4CIU6V (Proline)
      T18F433X4S (Norethindrone)
    • Publication Date:
      Date Created: 20140705 Date Completed: 20150406 Latest Revision: 20211021
    • Publication Date:
      20250114
    • Accession Number:
      10.1007/s00228-014-1711-0
    • Accession Number:
      24992979